Extremities
Hemoglobin reduction, total blood loss similar between oral and intravenous TXA use in primary TKA
DALLAS — Data presented here at the American Association of Hip and Knee Surgeons Annual Meeting indicated both hemoglobin reduction and total blood loss were comparable between patients who were administered tranexamic acid either orally or intravenously during primary total knee arthroplasty.
A switch “from [intravenous administration] to oral would provide us a cost savings of $23 million to $67 million per year to the health care system, and we as surgeons are the ones who are ordering the medications [that] can drive this reduction in cost,” Yale A. Fillingham, MD, said in his presentation of the James R. Rand Award-winning study.
